BOARD OF DIRECTORS
Adrian Adams
Adrian Adams was appointed Chairman and Chief Executive Officer on September 19, 2011. Prior to joining Neurologix, Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. in May 2011. Prior to Inspire, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. from December 2006 until February 2010. Under his leadership, Sepracor conducted multiple strategic business development activities, including the in-licensing of seven products and out-licensing deals with two major pharmaceutical companies, prior to its acquisition by Dainippon Sumitomo Pharma Co. Prior to joining Sepracor, Mr. Adams was President and Chief Executive Officer of Kos Pharmaceuticals, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. During his tenure he led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching $1 billion. During his 30 years of experience, Mr. Adams also held senior marketing positions at ICI (now part of AstraZeneca), SmithKline Beecham and Novartis. He has extensive expertise launching major global brands, and has driven successful corporate development activities including financing, product acquisitions, investments, in-licensing and company M&A activities. Mr. Adams received a B.S. in Chemistry from Salford University in the U.K. Mr. Adams serves as a director of Amylin Pharmaceuticals.
Adrian Adams was appointed Chairman and Chief Executive Officer on September 19, 2011. Prior to joining Neurologix, Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. in May 2011. Prior to Inspire, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. from December 2006 until February 2010. Under his leadership, Sepracor conducted multiple strategic business development activities, including the in-licensing of seven products and out-licensing deals with two major pharmaceutical companies, prior to its acquisition by Dainippon Sumitomo Pharma Co. Prior to joining Sepracor, Mr. Adams was President and Chief Executive Officer of Kos Pharmaceuticals, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. During his tenure he led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching $1 billion. During his 30 years of experience, Mr. Adams also held senior marketing positions at ICI (now part of AstraZeneca), SmithKline Beecham and Novartis. He has extensive expertise launching major global brands, and has driven successful corporate development activities including financing, product acquisitions, investments, in-licensing and company M&A activities. Mr. Adams received a B.S. in Chemistry from Salford University in the U.K. Mr. Adams serves as a director of Amylin Pharmaceuticals.
Andrew I. Koven
Andrew Koven was appointed President and Chief Administrative Officer on September 19, 2011. Prior to joining Neurologix, Mr. Koven held the position of Executive Vice President and Chief Administrative and Legal Officer at Inspire Pharmaceuticals, Inc., where he was responsible for the legal, intellectual property, CD&L and compliance departments through the acquisition of Inspire by Merck & Co, Inc. Prior to Inspire, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc. from March 2007 until February 2010. During his time at Sepracor, Mr. Koven was significantly involved with, and managed, all intellectual property, employment, regulatory, corporate governance, litigation, compliance, commercial transactions, sales and marketing policies and procedures and all CD&L and merger and acquisition activities, including the acquisition of Sepracor by Dainippon Sumitomo Pharma in 2009. Prior to Sepracor, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc. from 2003 through 2007. During this time he was responsible for the legal, compliance and quality assurance departments and was instrumental in all CD&L activities, including the acquisition of Kos by Abbott Laboratories at the end of 2006. Previously, he served as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003 and held positions of increasing responsibility at Warner-Lambert Company as Assistant General Counsel, Pharmaceuticals N.A. and Assistant General Counsel, Consumer Healthcare N.A. from 1993 to 2000. Mr. Koven also previously served as Counsel, Corporate and Investment Division for the Equitable Life Assurance Society of the United States and as a Corporate Associate in the law firm of Cahill Gordon & Reindell in New York City. Mr. Koven received a B.A. in Political Science from Dalhousie University and a LL.B. from Dalhousie University Law School and an LL.M. from Columbia University Law School in New York City.
Andrew Koven was appointed President and Chief Administrative Officer on September 19, 2011. Prior to joining Neurologix, Mr. Koven held the position of Executive Vice President and Chief Administrative and Legal Officer at Inspire Pharmaceuticals, Inc., where he was responsible for the legal, intellectual property, CD&L and compliance departments through the acquisition of Inspire by Merck & Co, Inc. Prior to Inspire, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc. from March 2007 until February 2010. During his time at Sepracor, Mr. Koven was significantly involved with, and managed, all intellectual property, employment, regulatory, corporate governance, litigation, compliance, commercial transactions, sales and marketing policies and procedures and all CD&L and merger and acquisition activities, including the acquisition of Sepracor by Dainippon Sumitomo Pharma in 2009. Prior to Sepracor, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc. from 2003 through 2007. During this time he was responsible for the legal, compliance and quality assurance departments and was instrumental in all CD&L activities, including the acquisition of Kos by Abbott Laboratories at the end of 2006. Previously, he served as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003 and held positions of increasing responsibility at Warner-Lambert Company as Assistant General Counsel, Pharmaceuticals N.A. and Assistant General Counsel, Consumer Healthcare N.A. from 1993 to 2000. Mr. Koven also previously served as Counsel, Corporate and Investment Division for the Equitable Life Assurance Society of the United States and as a Corporate Associate in the law firm of Cahill Gordon & Reindell in New York City. Mr. Koven received a B.A. in Political Science from Dalhousie University and a LL.B. from Dalhousie University Law School and an LL.M. from Columbia University Law School in New York City.
Cornelius E. Golding
Mr. Golding has been a director of the Corporation since August 2006. From 1981 to 2003, Mr. Golding served in various financial roles at Atlantic Mutual Insurance Company, a property and casualty insurance company in Madison, New Jersey. During his tenure with Atlantic Mutual, Mr. Golding first served as Vice President of Internal Audit and Comptroller before being appointed Senior Vice President. Mr. Golding was promoted to Chief Financial Officer in 1994 and served in this role until his retirement in 2003. Mr. Golding is currently a financial consultant to various property and casualty insurance companies and serves on the Board of Directors of National Atlantic Holdings Corporation, a property and casualty insurance company; Somerset Hills Bank Corp., a holding company for the Bank of Somerset Hills, a New Jersey bank; and various private companies including the United Auto Insurance Group of North Miami Beach, Florida. Mr. Golding is a Certified Public Accountant and holds a BBA in accounting from Saint John Fisher College and an MBA in finance from Fairleigh Dickenson University.
Mr. Golding has been a director of the Corporation since August 2006. From 1981 to 2003, Mr. Golding served in various financial roles at Atlantic Mutual Insurance Company, a property and casualty insurance company in Madison, New Jersey. During his tenure with Atlantic Mutual, Mr. Golding first served as Vice President of Internal Audit and Comptroller before being appointed Senior Vice President. Mr. Golding was promoted to Chief Financial Officer in 1994 and served in this role until his retirement in 2003. Mr. Golding is currently a financial consultant to various property and casualty insurance companies and serves on the Board of Directors of National Atlantic Holdings Corporation, a property and casualty insurance company; Somerset Hills Bank Corp., a holding company for the Bank of Somerset Hills, a New Jersey bank; and various private companies including the United Auto Insurance Group of North Miami Beach, Florida. Mr. Golding is a Certified Public Accountant and holds a BBA in accounting from Saint John Fisher College and an MBA in finance from Fairleigh Dickenson University.
Reginald L. Hardy
Mr. Hardy has been a director of the Corporation since February 18, 2010. Mr. Hardy founded Concordia Pharmaceuticals, Inc. He is President and a director of the drug development company which focuses on innovative cancer drug therapies. From 1992 through 1998, Mr. Hardy served as President of SANO Corporation, a pharmaceutical company focused on development of transdermal drug delivery systems. Mr. Hardy earned his BS degree in Pharmacy from the University of North Carolina – Chapel Hill, and his MBA from the University of North Carolina – Greensboro. The Board believes Mr. Hardy's background and executive experience in the pharmaceutical and drug industries is invaluable to the Corporation's business and strategies relating to its current products and its efforts to finance the development of such products. In particular, the Board looks to Mr. Hardy for assistance in negotiating investment banking and similar transactions.
Mr. Hardy has been a director of the Corporation since February 18, 2010. Mr. Hardy founded Concordia Pharmaceuticals, Inc. He is President and a director of the drug development company which focuses on innovative cancer drug therapies. From 1992 through 1998, Mr. Hardy served as President of SANO Corporation, a pharmaceutical company focused on development of transdermal drug delivery systems. Mr. Hardy earned his BS degree in Pharmacy from the University of North Carolina – Chapel Hill, and his MBA from the University of North Carolina – Greensboro. The Board believes Mr. Hardy's background and executive experience in the pharmaceutical and drug industries is invaluable to the Corporation's business and strategies relating to its current products and its efforts to finance the development of such products. In particular, the Board looks to Mr. Hardy for assistance in negotiating investment banking and similar transactions.
Clark A. Johnson
Clark A. Johnson has been a director of the Corporation since February 2004. Previously, Mr. Johnson served as Chairman of PSS World Medical, Inc., a national distributor of medical equipment and supplies to physicians, hospitals, nursing homes, and diagnostic imaging facilities since October 2000. From August 1985 to June 1998, Mr. Johnson served as Chief Executive Officer of Pier 1 Imports, a specialty retailer of imported decorative home furnishings, gifts and related items, also becoming Chairman in 1988. Currently, Mr. Johnson serves on the Board of Directors of various private companies including REFAC Optical Group, a provider of managed vision and professional eye care products and services and an affiliate of Palisade Capital Management, LLC; MetroMedia International Group, an international telecommunications company; World Factory, Inc., an international sourcing and product development company specializing in outdoor living and hardware products; and Brain Twist Inc., a specialty drink development company.
Clark A. Johnson has been a director of the Corporation since February 2004. Previously, Mr. Johnson served as Chairman of PSS World Medical, Inc., a national distributor of medical equipment and supplies to physicians, hospitals, nursing homes, and diagnostic imaging facilities since October 2000. From August 1985 to June 1998, Mr. Johnson served as Chief Executive Officer of Pier 1 Imports, a specialty retailer of imported decorative home furnishings, gifts and related items, also becoming Chairman in 1988. Currently, Mr. Johnson serves on the Board of Directors of various private companies including REFAC Optical Group, a provider of managed vision and professional eye care products and services and an affiliate of Palisade Capital Management, LLC; MetroMedia International Group, an international telecommunications company; World Factory, Inc., an international sourcing and product development company specializing in outdoor living and hardware products; and Brain Twist Inc., a specialty drink development company.
Martin J. Kaplitt, MD
Dr. Kaplitt served as Chairman of the Board of the Corporation from February 2004 through September 2011. Dr. Kaplitt served as Executive Chairman of the Corporation from September 2004 through February 23, 2007. He also served as President of the Corporation from February 2004 to September 2004 and was previously a director and President of Neurologix Research, Inc., the Corporation's predecessor, from August 1999 to February 2004. Dr. Kaplitt has been associated with North Shore University Hospital for over 30 years and has held a variety of positions including: Chief of Thoracic and Cardiovascular Surgery from 1971 to 1978, Associate Attending in Cardiovascular Surgery from 1978 to 2001 and Adjunct Associate Attending in Surgery from 2001 to present. He was also a Clinical Associate Professor of Surgery at Cornell University Medical College. Dr. Kaplitt was a director of the Trust Company of New Jersey from 1985 through May 2004, when it was acquired by North Fork Bankcorp of Long Island, NY. Dr. Kaplitt attended Cornell University and the State University of New York, Downstate Medical Center. Dr. Kaplitt is a fellow of the American College of Surgeons and the American College of Cardiology.
Dr. Kaplitt served as Chairman of the Board of the Corporation from February 2004 through September 2011. Dr. Kaplitt served as Executive Chairman of the Corporation from September 2004 through February 23, 2007. He also served as President of the Corporation from February 2004 to September 2004 and was previously a director and President of Neurologix Research, Inc., the Corporation's predecessor, from August 1999 to February 2004. Dr. Kaplitt has been associated with North Shore University Hospital for over 30 years and has held a variety of positions including: Chief of Thoracic and Cardiovascular Surgery from 1971 to 1978, Associate Attending in Cardiovascular Surgery from 1978 to 2001 and Adjunct Associate Attending in Surgery from 2001 to present. He was also a Clinical Associate Professor of Surgery at Cornell University Medical College. Dr. Kaplitt was a director of the Trust Company of New Jersey from 1985 through May 2004, when it was acquired by North Fork Bankcorp of Long Island, NY. Dr. Kaplitt attended Cornell University and the State University of New York, Downstate Medical Center. Dr. Kaplitt is a fellow of the American College of Surgeons and the American College of Cardiology.
Jeffrey B. Reich, MD
Dr. Reich has been a director of the Corporation since February 2005. Since January 2007, Dr. Reich has served as a healthcare analyst at Cramer Rosenthal McGlynn, a New York City-based investment and asset management firm. From 2002 through 2007, Dr. Reich served as Senior Analyst and Portfolio Manager at Merlin Biomed Group, a New York City-based asset management firm that invests globally in public and private healthcare companies. Dr. Reich has also served as Assistant Professor of Clinical Neurology at Weill Medical College of Cornell University since 1995. He received his medical degree from Weill Medical College of Cornell University in 1987.
Dr. Reich has been a director of the Corporation since February 2005. Since January 2007, Dr. Reich has served as a healthcare analyst at Cramer Rosenthal McGlynn, a New York City-based investment and asset management firm. From 2002 through 2007, Dr. Reich served as Senior Analyst and Portfolio Manager at Merlin Biomed Group, a New York City-based asset management firm that invests globally in public and private healthcare companies. Dr. Reich has also served as Assistant Professor of Clinical Neurology at Weill Medical College of Cornell University since 1995. He received his medical degree from Weill Medical College of Cornell University in 1987.
Elliott H. Singer
Mr. Singer has been a director of the Corporation since November 14, 2005. Mr. Singer is Managing Director of FairView Advisors, a financial services firm he founded in September 2001. Mr. Singer founded and served as Chief Executive Officer of A+ Network (formerly A+ Communications). Mr. Singer holds a BA from Tulane University and an MBA from the Leonard R. Stern School of Business at NYU.
Mr. Singer has been a director of the Corporation since November 14, 2005. Mr. Singer is Managing Director of FairView Advisors, a financial services firm he founded in September 2001. Mr. Singer founded and served as Chief Executive Officer of A+ Network (formerly A+ Communications). Mr. Singer holds a BA from Tulane University and an MBA from the Leonard R. Stern School of Business at NYU.
“… clinical outcomes [from the Phase 1 Parkinson’s disease study] were encouraging. Substantial improvements in both the off and on states were evident, beginning at three months after surgery and continuing until the end of the trial.”
The Lancet, June 23, 2007